Antihemophilic factor Intravenous, Injection and Thromboembolic events
Result of checking the interaction of drug Antihemophilic factor Intravenous, Injection and disease Thromboembolic events for safety when used together.
When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.
Consumer:Thromboembolic events have been reported in patients receiving antihemophilic factor/von Willebrand factor complex replacement therapy. Care should be exercised in the existence of known risk factors for thrombosis. Endogenous high levels of factor VIII have also been associated with thrombosis, but no causal relationship has been established. Caution is recommended and consider antithrombotic measures in all patients at risk who are receiving coagulation factor replacement therapy.
Generic Name: antihemophilic factor
Brand Name: Hemofil-M, Koate-DVI, Monoclate-P, Advate, Adynovate, Afstyla, Eloctate with Fc Fusion Protein, Helixate FS, Kogenate FS, Kovaltry, Novoeight, Nuwiq, Recombinate, Xyntha, Jivi, Obizur
Synonyms: Antihemophilic factor (human), Antihemophilic Factor (Human)